Latest market price
3.38
-0.28-7.65%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.18 | Insider Own | — | Shs Outstand | 99.45M | Perf Week | -16.13% |
| Market Cap | 336.13M | Forward P/E | — | EPS next Y | -0.81 | Insider Trans | -0.05% | Shs Float | 65.25M | Perf Month | -17.96% |
| Enterprise Value | 364.13M | PEG | — | EPS next Q | -0.34 | Short Float | 30.37% | Perf Quarter | -38.10% | ||
| Income | -215.00M | P/S | 2.85 | EPS this Y | — | Short Ratio | 10.68 | Perf Half Y | -60.51% | ||
| Sales | 118.00M | P/B | 25.86 | EPS next Y | — | ROA | -86.35% | Short Interest | 19.82M | Perf YTD | -70.99% |
| Book/sh | 0.13 | P/C | 2.33 | EPS next 5Y | — | ROE | -256.67% | 52W High | 13.15 -74.30% | Perf Year | -62.36% |
| Cash/sh | 1.45 | P/FCF | — | EPS past 3/5Y | — | ROIC | -114.61% | 52W Low | 3.34 1.20% | Perf 3Y | -2.87% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 337.95% 36.08% | Gross Margin | 73.89% | Volatility | 7.54% 6.53% | Perf 5Y | -63.26% |
| Dividend TTM | — | EV/Sales | 3.09 | EPS Y/Y TTM | — | Oper. Margin | -184.96% | ATR (14) | 0.28 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.28 | Sales Y/Y TTM | 4.42% | Profit Margin | -184.24% | RSI (14) | 29.77 | Recom | 2.50 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.48 | EPS Q/Q | -36.96% | SMA20 | -16.93% | Beta | 0.96 | Target Price | 15.00 |
| Payout | 0.00% | Debt/Eq | 13.23 | Sales Q/Q | 112.50% | SMA50 | -26.10% | Rel Volume | 1.07 | Prev Close | 3.66 |
| Employees | 195 | LT Debt/Eq | 13.23 | Earnings | Nov 05 | SMA200 | -54.28% | Avg Volume | 1.64M | Price | 3.38 |
| IPO Date | Dec 04, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -31.89% 7.46% | Net Debt/EBITDA | — | Volume | 1,754,250 | Change | -7.65% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-08-26 | Reiterated | Leerink Partners | Outperform | $18 → $15 |
| Apr-09-26 | Reiterated | Northland Securities | ||
| Mar-10-26 | Reiterated | Leerink Partners | Outperform | $18 |
| Nov-04-25 | Resumed | Roth Capital | Buy | |
| Sep-26-25 | Reiterated | Raymond James | Strong Buy | $22 |
| Aug-19-24 | Initiated | Cantor Fitzgerald | Overweight | |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy | $22 |
| Jul-25-24 | Initiated | Raymond James | Outperform | $18 |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform | $14 → $18 |
| Sep-20-23 | Downgrade | William Blair | Outperform → Market Perform |
Latest News· Times ET
Oct-29-26
Oct-29-2611:02AM
Oct-28-26
Oct-12-26
Oct-05-26
Oct-05-2608:45AM
03:28AM
03:22AM
Oct-04-26
Oct-04-2602:16PM
08:53AM
Oct-03-26
Oct-03-2608:41AM
Oct-02-26
Oct-02-2606:01PM
02:57PM
02:43PM
Oct-01-26
Oct-01-2604:30PM
Company
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 118 | 84 | 89 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 30 | 20 | 21 | 0 | — | — | — | — | — | |
| Gross Profit | 86 | 64 | 69 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 285 | 230 | 0 | 47 | — | — | — | — | — | |
| Research and Development | 15 | 13 | 20 | 20 | — | — | — | — | — | |
| Other Operating Expense | 3 | 0 | 52 | 1 | — | — | — | — | — | |
| Operating Income | -215 | -179 | -3 | -68 | — | — | — | — | — | |
| Interest Expense | 4 | 3 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 11 | 11 | 13 | — | — | — | — | — | |
| Net Income Before Taxes | -215 | -171 | 8 | -54 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -215 | -171 | 8 | -54 | — | — | — | — | — | |
| Net Income From Continuing Operations | -215 | -171 | 8 | -54 | — | — | — | — | — | |
| Net Income | -215 | -171 | 8 | -54 | — | — | — | — | — | |
| EPS (Recurring) | -2.18 | -1.74 | 0.08 | -0.57 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.18 | -1.74 | 0.08 | -0.57 | — | — | — | — | — | |
| EPS (Diluted) | -2.18 | -1.74 | 0.08 | -0.57 | — | — | — | — | — | |
| EBITDA | -207 | -167 | 8 | -54 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 135.08 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.84 | 13.73 | 11.50 | — | — | — | — | — | — | |
| Gross Margin | 72.88 | 76.19 | 77.53 | — | — | — | — | — | — | |
| Operating Margin | -182.20 | -213.10 | -3.37 | — | — | — | — | — | — | |
| Net Margin | -182.20 | -203.57 | 8.99 | — | — | — | — | — | — | |
| Shares Outstanding | 99 | 99 | 97 | 95 | — | — | — | — | — | |
| Market Capitalization | 335 | 1,153 | 1,023 | 521 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer | Jun 12 '26 | Option Exercise | 1.50 | 25,000 | 37,500 | 37,176 | Jun 12 |
| Karas Eric | Chief Commercial Officer | Jun 12 '26 | Sale | 10.00 | 25,000 | 250,000 | 12,176 | Jun 12 |
| Fitzpatrick Alexander A | Chief Legal Officer | Jun 12 '26 | Sale | 10.00 | 3,355 | 33,550 | 90,910 | Jun 12 |
| Dorsey Brian | Chief Operating Officer | Nov 13 '25 | Option Exercise | 0.64 | 21,828 | 13,970 | 32,617 | Nov 14 |
| Dorsey Brian | Chief Operating Officer | Nov 13 '25 | Sale | 8.71 | 21,828 | 190,050 | 10,789 | Nov 14 |
| Chakma Justin | Chief Business Officer | Nov 12 '25 | Option Exercise | 0.84 | 30,000 | 25,200 | 166,380 | Nov 14 |
| Chakma Justin | Chief Business Officer | Nov 12 '25 | Sale | 8.87 | 166,380 | 1,476,147 | 0 | Nov 14 |
| Lowenthal Richard E | PRESIDENT AND CEO | Aug 21 '25 | Sale | 14.49 | 50,000 | 724,345 | 1,196,494 | Aug 22 |
| Scott Kathleen D. | Chief Financial Officer | Aug 21 '25 | Option Exercise | 1.50 | 12,500 | 18,750 | 22,542 | Aug 22 |
| Scott Kathleen D. | Chief Financial Officer | Aug 21 '25 | Sale | 15.00 | 12,500 | 187,500 | 10,042 | Aug 22 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | Aug 20 '25 | Sale | 14.09 | 37,656 | 530,626 | 1,247,447 | Aug 21 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | Aug 19 '25 | Sale | 14.03 | 12,344 | 173,130 | 1,285,103 | Aug 21 |
| Karas Eric | Chief Commercial Officer | Jul 01 '25 | Option Exercise | 1.50 | 15,000 | 22,500 | 25,315 | Jul 03 |
| Karas Eric | Chief Commercial Officer | Jul 01 '25 | Sale | 16.99 | 15,000 | 254,861 | 10,315 | Jul 03 |
| Flynn James E | 10% Owner | Jun 27 '25 | Sale | 18.46 | 370,074 | 6,831,566 | 4,887,254 | Jul 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.